OR WAIT 15 SECS
Shell Ip, PhD, is a technical marketing specialist at Precision Nanosystems.
R. James Taylor, PhD, is CEO and co-founder at Precision Nanosystems.
Ilya Captain, PhD, is a field application scientist at Precision Nanosystems.
Dave Reichert is a technical marketing writer at Precision Nanosystems.
This review examines how microfluidics has been used in the formulation, preclinical, and clinical development of gene-delivery nanoparticles.
Microfluidics is fast becoming an essential tool for encapsulating nucleic acids. Microfluidics allows fine control over process parameters, enabling optimization of nanoparticle characteristics and nucleic acid encapsulation. The continuous, inherently scalable nature of the microfluidic process allows formulations to be optimized at low volumes, before being scaled-up using multiple microfluidic mixers in parallel. This review examines how microfluidics has been used in the formulation, preclinical, and clinical development of gene-delivery nanoparticles.
BioPharm International eBook: Development Strategies for Emerging Therapies
When referring to this article, please cite it as S. Ip, D. Reichert, I. Captain, and R. J. Taylor, "Accelerating Genetic Medicine R&D Using Microfluidics," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).